NCT05717140View on ClinicalTrials.gov

Aerosolized Sargramostim Added to Immunotherapy for the Treatment of Patients With Metastatic Melanoma to the Lung

PHASE1WithdrawnINTERVENTIONAL
0
Timeline

Start Date

October 28, 2025

Primary Completion Date

January 28, 2026

Study Completion Date

January 28, 2026

Conditions
Clinical Stage IV Cutaneous Melanoma AJCC v8Metastatic Malignant Neoplasm in the LungMetastatic MelanomaRecurrent MelanomaUnresectable Melanoma
Interventions
BIOLOGICAL

Aerosol Sargramostim

Given via inhalation with nebulizer

PROCEDURE

Biospecimen Collection

Undergo collection of blood samples

PROCEDURE

Computed Tomography

Undergo CT

PROCEDURE

Magnetic Resonance Imaging

Undergo MRI

OTHER

Medical Device Usage and Evaluation

Use Aerogen Solo nebulization device

BIOLOGICAL

Nivolumab

Given IV

Trial Locations (1)

55905

Mayo Clinic in Rochester, Rochester

Sponsors

Lead Sponsor

Mayo Clinic
All Listed Sponsors
lead

Mayo Clinic

OTHER

NCT05717140 - Aerosolized Sargramostim Added to Immunotherapy for the Treatment of Patients With Metastatic Melanoma to the Lung | Biotech Hunter | Biotech Hunter